Repeat revascularization after contemporary percutaneous coronary intervention: An evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year

Circulation: Cardiovascular Interventions

Volumn 5, Issue 6, 2012, Pages 772-782

  Stolker, Joshua M ^a   Cohen, David J ^b   Kennedy, Kevin F ^b   Pencina, Michael J ^c   Lindsey, Jason B ^b   Mauri, Laura ^c   Cutlip, Donald E ^c   Kleiman, Neal S ^d  

^a SAINT LOUIS UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Percutaneous coronary intervention; Restenosis; Revascularization; Stent

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETREATMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84873671086     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.967802     Document Type: Article

References (33)

1. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110:1226-1230.
2. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-3206.
3. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED; American College of Cardiology National Cardiovascular Data Registry. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478-1481.
4. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010;56:254-263.
5. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Out-comes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000.
6. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS; EVENT Registry In-vestigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-2009.
7. Jeremias A, Ruisi CP, Kirtane AJ, Lee T, Sylvia B, Pinto DS, Ho KK, Cutlip DE, Carrozza JP Jr., Cohen DJ. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'. Coron Artery Dis. 2008;19:111-115.
8. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-352.
9. Alderman EL, Kip KE, Whitlow PL, Bashore T, Fortin D, Bourassa MG, Lesperance J, Schwartz L, Stadius M; Bypass Angioplasty Revascularization Investigation. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol. 2004;44:766-774.
10. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005;111:143-149.
11. Lemesle G, de Labriolle A, Bonello L, Torguson R, Kaneshige K, Xue Z, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R. Incidence, predictors, and outcome of new, subsequent lesions treated with percutaneous coronary intervention in patients presenting with myocardial infarction. Am J Cardiol. 2009;103:1189-1195.
12. Loutfi M, Mulvihill NT, Boccalatte M, Farah B, Fajadet J, Marco J. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc Interv. 2003;58:451-454.
13. Zhao XQ, Kosinski AS, Barnhart HX, Superko HR, King SB 3rd. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. Med Sci Monit. 2003;9:CR48-CR54.
14. Ryan J, Linde-Zwirble W, Engelhart L, Cooper L, Cohen DJ. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program. Circulation. 2009;119:952-961.
15. Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, Kleiman N; EVENT Investigators. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J. 2005;150:887-892.
16. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
17. Klein J, Moeschberger M. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer Publishers; 2003.
18. Hannan EL, Samadashvili Z, Walford G, Holmes DR Jr., Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, King SB, 3rd. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv. 2010;3:22-31.
19. Brener SJ, Milford-Beland S, Roe MT, Bhatt DL, Weintraub WS, Brindis RG; American College of Cardiology National Cardiovascular Database Registry. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Am Heart J. 2008;155:140-146.
20. Kong JA, Chou ET, Minutello RM, Wong SC, Hong MK. Safety of single versus multi-vessel angioplasty for patients with acute myocardial infarc-tion and multi-vessel coronary artery disease: report from the New York State Angioplasty Registry. Coron Artery Dis. 2006;17:71-75.
21. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC Jr., Laster SB, Johnson WL, Daniels WC, Barth CW, Giorgi LV, Rutherford BD. Mul-tivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J. 2004;148:493-500.
22. Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, Butter C, Engstrøm T, Hassager C, Machado FP, Pedrazzini G, Wagner DR, Schamberger R, Kerber S, Mathey DG, Schofer J, Engström AE, Henriques JP. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54:2430-2434.
23. Chacko R, Mulhearn M, Novack V, Novack L, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC Cardiovasc Interv. 2009;2:498-503.
24. Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovasc Interv. 2009;2:504-512.
25. Tousek P, Pavei A, Oreglia J, Martin G, Sharif F, Fajadet J, Farah B. Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era. EuroIntervention. 2009;4:588-592.
26. Centers for Disease Control and Prevention. Vital signs: Prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:1-6.
27. Centers for Disease Control and Prevention. Vital signs: Prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:7-12.
28. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
29. Giedd KN, Bergmann SR. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. J Am Coll Cardiol. 2004;43:328-336.
30. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008;155:56-61.
31. Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J. 2008;156:1074-1079.
32. von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A, Böse D, Eggebrecht H, Neumann T, Gössl M, Wieneke H, Erbel R. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation. 2004;110:1579-1585.
33. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224.